NR 565 MIDTERM EXAM NEWEST 2025/2026 COMPLETE
QUESTIONS AND CORRECT DETAILED DETAILED ANSWERS
(VERIFIED DETAILED ANSWERS) |BRAND NEW VERSION!!
G-Protien coupled receptors and how they interact with drugs - DETAILED ANSWER-G-protein
coupled receptors (GPCR) interact with drugs through 7 regions of proteins that span and
innervate the cell membrane and trap the molecule into the receptor site like an interwoven basket
(Insel & Sriram, 2018). Drugs can then enter this space and interact with the GRCP. A specific
interaction and binding with a site on one or more of the regions of proteins within the GPCR, and
drugs bound with the GRCP can stimulate the release of G proteins that can interact with various
effector proteins to create physiological responses within the body (Insel & Sriram, 2018). This
process occurs through secondary messengers (such as cAMP) which creates the extracellular
interactions produced by the drug binding to the GRCP.
What neurotransmitters are excitatory? - DETAILED ANSWER-amino acids such as glycine,
aspartate, and glutamate are excitatory (Woo & Robinson, p.16, 2016).
Which is the most common CYP enzyme in the body? What role does it play? - DETAILED
ANSWER-According to the textbook, the CYP3A4 is the most important enzyme in the body.
CYP3A4 is responsible for the metabolism of more than 50% of medications and is considered a
major drug metabolizing enzyme. CYP3A4 can be found in the liver, as well as the lining of the GI
tract. Due to this location, food can also influence this CYP. One example of this is grapefruit
juice, which can inhibit CYP3A4.
Medications that are metabolized by CYP3A4 include antimicrobials, calcium channel blockers,
antihistamines, anticonvulsants, azole antifungals, and corticosteroids (Woo, & Robinson, 2016).
, What is the clinical significance of being an ultra-rapid CYP2D6 metabolizer? - DETAILED
ANSWER-People who are ultra-rapid metabolizers have high activity of CYP2D6 enzymes that
break down certain medicines rapidly and are likely to need different doses or even a different
medicine. Drug dose, response, and toxicity risk of betablockers, antidepressants,
antiarrhythmics, and opioid analgesics are dependent on
CYP2D6 pharmacogenetics (Ayazseven et al., 2020). Knowing the result of the CYP2D6 test and
which group the patient falls into such as poor metabolizers, intermediate metabolizers, or ultra-
rapid metabolizers, will help nurse practitioners prescribe the right medication and dosage for the
patient.
What would be the concern if a drug is a CYP450indicer? How that might affect the metabolism of
another drug the patient is taking? - DETAILED ANSWER-Cytochrome P450 enzymes are in
cells throughout the body, primarily found in liver cells (Girvan & Munro, 2016). These enzymes
are essential for the metabolism of many medications. Cytochrome P450 enzymes can act as an
inducer or inhibitor of metabolism. When a medication induces the CYP450 enzyme that increases
the rate of metabolism (Girvan & Munro, 2016). This can impact the effectiveness of other
medications. For example, medication A induces CYP450 enzyme activity, therefore medication B
will be metabolized quicker and have a less therapeutic effect.
Explain the significance of a drug being an inhibitor of P-glycoprotein? (see text) - DETAILED
ANSWER-P-glycoprotein (P-gp) is the main barrier of the body and it affects the proper delivery
of drugs and causes drug resistance in our body. P-gp is an efflux membrane transporter, that can
be found throughout the body and it controls the cellular uptake and the distribution of synthetic
substances, chemicals, and toxins. Drugs are chemicals and P-gp hinders the absorption,
permeability, and retention of the drugs, extruding them out of the cells. This adversely affects
drug therapies and fails to yield good results, for example in therapies like using chemo agents in
cancer treatments. In this case, proper inhibition of P-gp is important to increase cellular uptake,
transport, and half-lives of drugs. The drug is an inhibitor of P-gp that would help in the cost-
effective treatment for disease conditions without wasting an extra amount of medicines. It will
help to shorten the treatment time and speedy recovery of the patient (Abebe et al., 2019; Woo &
Robinson, 2016).
QUESTIONS AND CORRECT DETAILED DETAILED ANSWERS
(VERIFIED DETAILED ANSWERS) |BRAND NEW VERSION!!
G-Protien coupled receptors and how they interact with drugs - DETAILED ANSWER-G-protein
coupled receptors (GPCR) interact with drugs through 7 regions of proteins that span and
innervate the cell membrane and trap the molecule into the receptor site like an interwoven basket
(Insel & Sriram, 2018). Drugs can then enter this space and interact with the GRCP. A specific
interaction and binding with a site on one or more of the regions of proteins within the GPCR, and
drugs bound with the GRCP can stimulate the release of G proteins that can interact with various
effector proteins to create physiological responses within the body (Insel & Sriram, 2018). This
process occurs through secondary messengers (such as cAMP) which creates the extracellular
interactions produced by the drug binding to the GRCP.
What neurotransmitters are excitatory? - DETAILED ANSWER-amino acids such as glycine,
aspartate, and glutamate are excitatory (Woo & Robinson, p.16, 2016).
Which is the most common CYP enzyme in the body? What role does it play? - DETAILED
ANSWER-According to the textbook, the CYP3A4 is the most important enzyme in the body.
CYP3A4 is responsible for the metabolism of more than 50% of medications and is considered a
major drug metabolizing enzyme. CYP3A4 can be found in the liver, as well as the lining of the GI
tract. Due to this location, food can also influence this CYP. One example of this is grapefruit
juice, which can inhibit CYP3A4.
Medications that are metabolized by CYP3A4 include antimicrobials, calcium channel blockers,
antihistamines, anticonvulsants, azole antifungals, and corticosteroids (Woo, & Robinson, 2016).
, What is the clinical significance of being an ultra-rapid CYP2D6 metabolizer? - DETAILED
ANSWER-People who are ultra-rapid metabolizers have high activity of CYP2D6 enzymes that
break down certain medicines rapidly and are likely to need different doses or even a different
medicine. Drug dose, response, and toxicity risk of betablockers, antidepressants,
antiarrhythmics, and opioid analgesics are dependent on
CYP2D6 pharmacogenetics (Ayazseven et al., 2020). Knowing the result of the CYP2D6 test and
which group the patient falls into such as poor metabolizers, intermediate metabolizers, or ultra-
rapid metabolizers, will help nurse practitioners prescribe the right medication and dosage for the
patient.
What would be the concern if a drug is a CYP450indicer? How that might affect the metabolism of
another drug the patient is taking? - DETAILED ANSWER-Cytochrome P450 enzymes are in
cells throughout the body, primarily found in liver cells (Girvan & Munro, 2016). These enzymes
are essential for the metabolism of many medications. Cytochrome P450 enzymes can act as an
inducer or inhibitor of metabolism. When a medication induces the CYP450 enzyme that increases
the rate of metabolism (Girvan & Munro, 2016). This can impact the effectiveness of other
medications. For example, medication A induces CYP450 enzyme activity, therefore medication B
will be metabolized quicker and have a less therapeutic effect.
Explain the significance of a drug being an inhibitor of P-glycoprotein? (see text) - DETAILED
ANSWER-P-glycoprotein (P-gp) is the main barrier of the body and it affects the proper delivery
of drugs and causes drug resistance in our body. P-gp is an efflux membrane transporter, that can
be found throughout the body and it controls the cellular uptake and the distribution of synthetic
substances, chemicals, and toxins. Drugs are chemicals and P-gp hinders the absorption,
permeability, and retention of the drugs, extruding them out of the cells. This adversely affects
drug therapies and fails to yield good results, for example in therapies like using chemo agents in
cancer treatments. In this case, proper inhibition of P-gp is important to increase cellular uptake,
transport, and half-lives of drugs. The drug is an inhibitor of P-gp that would help in the cost-
effective treatment for disease conditions without wasting an extra amount of medicines. It will
help to shorten the treatment time and speedy recovery of the patient (Abebe et al., 2019; Woo &
Robinson, 2016).
